A Phase 2, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Lenzilumab (Primary)
- Indications Asthma
- Focus Pharmacogenomic; Proof of concept; Therapeutic Use
- Sponsors Humanigen; KaloBios Pharmaceuticals
- 07 Aug 2017 According to a Humanigen media release, KaloBios Pharmaceuticals changed its name to Humanigen.
- 29 Jan 2014 Top-line results published in a KaloBios media release.
- 29 Jan 2014 Primary endpoint 'Forced-expiratory-volume-in-1-second' has not been met according to top-line results published in a KaloBios media release